BioMarin provided a series of updates on their investigational hemophilia A gene therapy candidate valoctocogene roxaparvovec.
The FDA has lifted a hold on clinical studies involving the investigational therapy fitusiran.
This agreement allows Shire to conduct research on the use of Rani Pill™ technology for the oral delivery of factor VIII therapy for patients with hemophilia A.
Spark provided clinical trial updates on the company’s investigational gene therapies for hemophilia A and B, SPK-8011 and SPK-9001.
NHF is closely monitoring numerous issues affecting the bleeding disorders community including tax reform and reauthorization of CHIP.
Genentech recently reported results from the phase III HAVEN 3 study, which showed that the prophylactic use of HEMLIBRA® led to significantly reduced bleeds in adult and adolescent patients with h
NHF is pleased to announce Christopher J. Ng, MD, Assistant Professor of Pediatrics, University of Colorado Denver, as the recipient of the 2017 NHF/Novo Nordisk Career Development Award (CDA).
This online learning activity for healthcare providers is focused on the developmental and psychosocial issues unique to children with bleeding disorders, specifically those from infancy through preadolescence.
The study seeks to shed light on the barriers people with hemophilia who are obese or overweight have to losing weight.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car